Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alizé Pharma 3 Raises €67m To Build ‘Fully Fledged’ Biotech

Executive Summary

The Series A financing positions Alizé to take a rival to Shire’s Natpara through to clinical proof of concept over the next few years.

You may also be interested in...



LSP Closes Mega Life Sciences Fund For Europe, But US Still Way Ahead

A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.

Finance Watch: Cell And Gene Therapy Fundraising Down Overall In Q2, But VC Deals Still Soared

Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.

Millendo Gets European Foothold With Alizé Acquisition

The US company is getting hold of livoletide, the French firm's late-stage ready compound for reducing hyperphagia, or insatiable hunger, in patients suffering from the rare genetic disease Prader-Willi Syndrome.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel